Solventum Corp (SOLV)
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
- Ticker
- SOLV
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Market cap
- $15.36B
- 52-week range
- $62.38 - $94.16
Valuation
- Share price
- $90.38 (close of Nov 6, 2026)
- P/E (TTM)
- 100.42x
- Price to book
- 3.20x
- Enterprise value
- $20.18B
- Book value per share
- $28.27
Price performance
| Period | Change |
|---|---|
| 1 day | +3.67% |
| 5 days | +11.13% |
| 1 month | +3.84% |
| 3 months | +8.94% |
| 6 months | +27.31% |
| Year to date | +14.06% |
| 1 year | +36.36% |
| All time | +12.98% |
Short interest
- As of
- Oct 15, 2026
- Short % of float
- 3.44%
- Shares short
- 4.95M
- Days to cover
- 4.71
- Change since prior report
- +1.18%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed SOLV trades
Alan Armstrong · French Hill · Julie Johnson · Ron Wyden · Tommy Tuberville
Super investors holding SOLV
Nelson Peltz (Trian Fund Management) · Christopher Davis (Davis Selected Advisers) · Richard Pzena (Pzena Investment Management) · Ray Dalio (Bridgewater Associates) · Ken Griffin (Citadel) · Mairs & Power (Mairs & Power Inc)
Profitability and growth
- Return on equity
- 30.82%
- Return on invested capital
- 20.07%
- Return on assets
- 10.89%
- Return on capital employed
- 19.55%
- Gross margin
- 53.47%
- Net margin
- 18.69%
- EBITDA margin
- 32.07%
- Revenue growth
- 0.86%
- Net income growth
- 224.84%
- Free cash flow growth
- -101.24%
Cash flow and balance sheet
- Current ratio
- 1.03x
- Net debt to EBITDA
- 5.09x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Revenue
- $8.32B
- Cost of revenue
- $2.33B
- Gross profit
- $4.45B
- EBITDA
- $2.67B
- Net income
- $1.56B
- Earnings per share
- $8.94
- Research and development
- $739.00M
- Interest expense
- $347.00M
- Shares outstanding
- 174.10M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $8.32B | $4.45B | $1.56B | $8.94 |
| 2024-12-31 | $8.25B | $4.59B | $479.00M | $2.77 |
| 2023-12-31 | $8.20B | $4.69B | $1.35B | $7.79 |
| 2022-12-31 | $8.13B | $4.70B | $1.34B | $7.78 |
| 2021-12-31 | $8.17B | $4.92B | $1.46B | $8.47 |
| 2020-12-31 | $7.28B | $4.32B | $1.14B | $6.60 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 53.47% | 18.69% | 30.82% | 20.07% |
| 2024-12-31 | 55.65% | 5.80% | 16.19% | 8.29% |
| 2023-12-31 | 57.25% | 16.42% | 11.54% | 6.87% |
| 2022-12-31 | 57.75% | 16.52% | 11.44% | 11.35% |
| 2021-12-31 | 60.25% | 17.87% | 12.11% | 11.97% |
| 2020-12-31 | 59.26% | 15.63% | - | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $878.00M | $5.04B |
| 2024-12-31 | $762.00M | $7.81B |
| 2023-12-31 | $194.00M | $8.30B |
| 2022-12-31 | $61.00M | $68.00M |
| 2021-12-31 | $91.00M | $83.00M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | -$10.00M | $161.00M |
| 2024-12-31 | $805.00M | $112.00M |
| 2023-12-31 | $1.63B | $39.00M |
| 2022-12-31 | $1.43B | $37.00M |
| 2021-12-31 | $1.93B | $38.00M |
| 2020-12-31 | $1.75B | $35.00M |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-11-05 | Sep 2026 | $1.35 |
| 2026-08-05 | Jun 2026 | $1.91 |
| 2026-05-05 | Mar 2026 | $1.35 |
| 2026-02-26 | Dec 2025 | $1.50 |
| 2025-11-06 | Sep 2025 | $1.43 |
| 2025-08-07 | Jun 2025 | $1.45 |
| 2025-05-08 | Mar 2025 | $1.19 |
| 2025-02-27 | Dec 2024 | $1.31 |
Filings and sources
- Company website
- solventum.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Baxter International Inc (BAX) · West Pharmaceutical Services Inc (WST) · Avantor, Inc. (AVTR) · Alcon Inc (ALC) · Cooper Companies, Inc. (COO) · ResMed Inc (RMD) · Align Technology Inc (ALGN) · Medline Inc. (MDLN)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades